Glaxo get Indian market rights for Japanese medicineMay 5th, 2008 - 3:23 pm ICT by admin
Mumbai May 5 (IANS) Pharma major GlaxoSmithKline (GSK) has bagged a deal to sell Japan based Astellas Pharma Inc’s popular injectible anti-fungal agent Micafungin in India. Announcing this Monday, GlaxoSmithKline said the deal gives it exclusive market rights for the sale of Micafungin (brand name Mycamine) in India.
Micafungin, belonging to a new class of anti-fungal agents used in the medication of deep seated Candida infections, was initially approved by Japanese Agency in 2002, by the US in 2005 followed by other countries.
Tags: astellas pharma inc, brand name, candida, candida infections, fungal agents, glaxo, glaxosmithkline, gsk, India, japan, japanese agency, japanese medicine, medication, medicine, micafungin, mycamine